Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Jacquet

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Cancer Research|May 19, 2006
Intratumor CD4 T-cell accumulation requires stronger priming than for expansion and lymphokine secretionNathalie T Joncker, Julie Helft, Alexandra Jacquet, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 4, 2015
Modeling the specific CD4+ T cell response against a tumor neoantigenHéloïse Flament, Ruby Alonso Ramirez, Virginie Prémel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 9, 2017
Correction: Modeling the Specific CD4<sup>+</sup> T cell Response against a Tumor NeoantigenHéloïse Flament, Ruby Alonso Ramirez, Virginie Prémel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 2010
Long peptide vaccination can lead to lethality through CD4+ T cell-mediated cytokine stormHiroshi Kitamura, Christine Sedlik, Alexandra Jacquet, et al.
Blood|June 10, 2008
Antigen-specific T-T interactions regulate CD4 T-cell expansionJulie Helft, Alexandra Jacquet, Nathalie T Joncker, et al.
Cancer Research|August 15, 2009
The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cellsMagali Terme, Grégoire Mignot, Evelyn Ullrich, et al.
Mabs|February 5, 2014
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibodyCéline Monnet, Sylvie Jorieux, Nathalie Souyris, et al.
Investigative Ophthalmology & Visual Science|April 25, 2013
Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomasRym Ben Abdelwahed, Sabrina Donnou, Hanane Ouakrim, et al.
International Journal of Cancer|April 30, 2022
CANTO-RT: Skin toxicities evaluation of a multicentre large prospective cohort of irradiated patients for early-stage breast cancerSofiane Allali, Matthieu Carton, Thomas Sarrade, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2022
Impact of radiation therapy on fatigue at 1 year in breast cancer survivors in the prospective multicentre CANcer TOxicity cohortYoussef Ghannam, Antonio Di Meglio, Thomas Sarrade, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Cancer Research|May 19, 2006
Intratumor CD4 T-cell accumulation requires stronger priming than for expansion and lymphokine secretionNathalie T Joncker, Julie Helft, Alexandra Jacquet, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 4, 2015
Modeling the specific CD4+ T cell response against a tumor neoantigenHéloïse Flament, Ruby Alonso Ramirez, Virginie Prémel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 9, 2017
Correction: Modeling the Specific CD4<sup>+</sup> T cell Response against a Tumor NeoantigenHéloïse Flament, Ruby Alonso Ramirez, Virginie Prémel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 2010
Long peptide vaccination can lead to lethality through CD4+ T cell-mediated cytokine stormHiroshi Kitamura, Christine Sedlik, Alexandra Jacquet, et al.
Blood|June 10, 2008
Antigen-specific T-T interactions regulate CD4 T-cell expansionJulie Helft, Alexandra Jacquet, Nathalie T Joncker, et al.
Cancer Research|August 15, 2009
The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cellsMagali Terme, Grégoire Mignot, Evelyn Ullrich, et al.
Mabs|February 5, 2014
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibodyCéline Monnet, Sylvie Jorieux, Nathalie Souyris, et al.
Investigative Ophthalmology & Visual Science|April 25, 2013
Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomasRym Ben Abdelwahed, Sabrina Donnou, Hanane Ouakrim, et al.
International Journal of Cancer|April 30, 2022
CANTO-RT: Skin toxicities evaluation of a multicentre large prospective cohort of irradiated patients for early-stage breast cancerSofiane Allali, Matthieu Carton, Thomas Sarrade, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2022
Impact of radiation therapy on fatigue at 1 year in breast cancer survivors in the prospective multicentre CANcer TOxicity cohortYoussef Ghannam, Antonio Di Meglio, Thomas Sarrade, et al.
Pageof 2